Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.

The biotech company intends to explore ways to move ahead with developing the treatment, including seeking a new collaborator ...

Chad Stevens traveled from Idaho to Omaha's Nebraska Medical Center, where he became the hospital's first patient to receive ...

The FDA recently approved the treatment by Novo Nordisk for hemophilia A or B with inhibitors, designed to prevent or reduce ...

Promising early results from an ongoing randomized, open-label, single-arm, Phase 3 study could pave the way for a Pfizer ...

Sangamo Therapeutics (SGMO) stock plunged as Pfizer (PFE) ends collaboration on hemophilia A gene therapy. Find out the ...

Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...

Columnist Jennifer Lynne knows that finding a sense of community can be challenging, but she's also learned it's worth it.

The approval of concizumab-mtci (Alhemo) injection marks a significant milestone in managing hemophilia A and B with ...

A staff member at the Nebraska Medical Center prepares to infuse Idaho resident Chad Stevens with a gene therapy for ...

Hemophilia A ... to spontaneous and severe bleeding after injuries or surgery. Sangamo said it remains focused on advancing its other therapy for the inherited disorder Fabry disease toward ...

Concizumab is a tissue factor pathway inhibitor antagonist that enhances factor Xa production during the initiation phase of coagulation. This production improves thrombin generation and clot ...